Studies have demonstrated the potential of dopamine receptor D2 activators in alleviating oxidative damage following stroke (Zhang et al., 2023; Pearson-Fuhrhop et al., 2013), thereby identifying dopamine receptors as viable treatment targets for stroke. This evidence concerns the gene DRD2 and stroke disorder.